[go: up one dir, main page]

AR038972A1 - Derivados de bencimidazol n3 alquilado como inhibidores de mek - Google Patents

Derivados de bencimidazol n3 alquilado como inhibidores de mek

Info

Publication number
AR038972A1
AR038972A1 ARP030100888A ARP030100888A AR038972A1 AR 038972 A1 AR038972 A1 AR 038972A1 AR P030100888 A ARP030100888 A AR P030100888A AR P030100888 A ARP030100888 A AR P030100888A AR 038972 A1 AR038972 A1 AR 038972A1
Authority
AR
Argentina
Prior art keywords
nr3r4
heteroaryl
aryl
heterocyclyl
nr5c
Prior art date
Application number
ARP030100888A
Other languages
English (en)
Inventor
Eli M Wallace
Joe P Lyssikatos
Allison L Marlow
T Brian Hurley
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AR038972A1 publication Critical patent/AR038972A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composición farmacéutica que los contiene, junto con un vehículo y su uso como inhibidor de la actividad de MEK y para tratamiento de enfermedades hiperproliferativas, como cáncer e inflamación. Reivindicación 1: Un compuesto de la fórmula (1) y sales farmacéuticamente aceptadas, prodrogas y solvatos en donde: R1, R2, R9 y R10 se seleccionan independientemente de H, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, NR5C(O)NR3R4, -NR5C(NCN)NR3R, -NR3R4, o alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, -S(O)j(alquilo C1-6), -S(O)j(CR4R5)m-arilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, -O(CR4R5)m-arilo, -NR4(CR4R5)m-arilo, -O(CR4R5)m-heteroarilo, NR4(CR4R5)m-heteroarilo, -O(CR4R5)m-heterociclilo, o -NR4(CR4R5)m-heterociclilo, en donde cada porción alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo, y heterociclilo es optativamente sustituida con 1 a 5 grupos seleccionados independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4,-NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo; R3 se selecciona de H, trifluorometilo, o alquilo C1-10, (CH2)n-cicloalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, donde cada porción alquilo, cicloalquilo, arilo, heteroarilo, y heterociclilo es optativamente sustituida con 1 a 5 grupos seleccionados independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, NR4SO2R6, SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -SR3, -S(O)R3, SO2R3, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo; R3 y R4 junto con el átomo al cual están unidos forman un anillo carbocíclico, heteroarilo, o heterocíclico de 4 a 10 miembros, cada uno de los cuales es optativamente sustituido con 1 a 3 grupos seleccionados independientemente de halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, -SO2NR3R4,-C(O)R3, -C(O)OR3, -OC(O)R3 -NR4C(O)R3, -C(O)NR3R4, -SO2R3, -NR3R4, -NR5C(O)NR3R4, NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo; R4 y R5 independientemente representan H o alquilo C1-6, o R4 y R5 junto con el átomo al cual están unidos forman un anillo carbocíclico, de heteroarilo o heterocíclico, cada uno de los cuales es optativamente sustituido con 1 a 3 grupos seleccionados independientemente de halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)R6, -C(O)NR3R4, -SO2R3, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo; R6 se selecciona de trifluorometilo o alquilo C1-10, cicloalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, donde cada porción alquilo, cicloalquilo, arilo, heteroarilo o heterociclilo es optativamente sustituida con 1 a 5 grupos seleccionados independientemente de oxo, halógeno, ciano, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)R6, C(O)NR3R4, -SO2R3, NR3R4, -NR5C(O)NR3R4, NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo; R7 se selecciona de alquilo C1-10, cicloalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, donde cada porción alquilo, cicloalquilo, arilo, heteroarilo, heterociclilo es optativamente sustituida con 1 a 5 grupos seleccionados independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido , NR4SO2R6, SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -SO2R3, -NR4C(O)OR6, NR4C(O)R3, -C(O)NR3R4, NR3R4, NR3C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aril, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo; W se selecciona de -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, C(O)R4OR3, -C(O)(cicloalquilo C3-10), -C(O)(alquilo C1-10), C(O)(arilo), -C(O)(heteroarilo, y -C(O)(heterociclilo) cada uno de los cuales es optativamente sustituido con 1-5 grupos independientemente seleccionados de -NR3R4, OR3, -R3, o alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cada uno de los cuales es optativamente sustituido con 1 o 2 grupos independientemente seleccionados de -NR3R4 y -OR3;n es 0,1,2,3 o 4; m es 0,1,2,3,4,o 5, y j es 1 o 2.
ARP030100888A 2002-03-13 2003-03-13 Derivados de bencimidazol n3 alquilado como inhibidores de mek AR038972A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36416402P 2002-03-13 2002-03-13

Publications (1)

Publication Number Publication Date
AR038972A1 true AR038972A1 (es) 2005-02-02

Family

ID=28041882

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100888A AR038972A1 (es) 2002-03-13 2003-03-13 Derivados de bencimidazol n3 alquilado como inhibidores de mek

Country Status (18)

Country Link
US (2) US20030216460A1 (es)
EP (1) EP1482944A4 (es)
JP (1) JP2005526076A (es)
KR (1) KR20040098013A (es)
CN (1) CN1652792A (es)
AR (1) AR038972A1 (es)
AU (1) AU2003220202A1 (es)
CA (1) CA2478534A1 (es)
CO (1) CO5611145A2 (es)
DO (1) DOP2003000614A (es)
IL (1) IL163996A0 (es)
MX (1) MXPA04008894A (es)
PA (1) PA8569201A1 (es)
PL (1) PL378635A1 (es)
RU (1) RU2300528C2 (es)
TW (1) TW200406203A (es)
UA (1) UA76837C2 (es)
WO (1) WO2003077855A2 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2003077914A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
ES2331246T3 (es) 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP5042626B2 (ja) 2003-09-22 2012-10-03 エス＊バイオ プライベート リミティッド ベンズイミダゾール誘導体：製造及び医薬適用
AU2004293018B2 (en) * 2003-11-19 2010-02-18 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
CA2546754A1 (en) * 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
UA94571C2 (en) 2004-10-20 2011-05-25 Мерк Сероно С.А. 3-arylamino pyridine derivatives
ATE443063T1 (de) * 2004-12-01 2009-10-15 Merck Serono Sa Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
ES2378760T3 (es) 2005-05-18 2012-04-17 Array Biopharma, Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
WO2007002157A2 (en) 2005-06-23 2007-01-04 Array Biopharma Inc. Process for preparing benzimidazole compounds
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
CN101341132A (zh) * 2005-12-21 2009-01-07 阿斯利康(瑞典)有限公司 作为mek抑制剂用于治疗癌症的6-(4-溴-2-氯-苯基氨基)-7-氟-n-(2-羟基乙氧基)-3-甲基-3h-苯并咪唑-5-甲酰胺的甲苯磺酸盐
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
KR20150041164A (ko) 2006-07-06 2015-04-15 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 시클로펜타〔ｄ〕피리미딘
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ZA200901009B (en) * 2006-08-21 2010-05-26 Genentech Inc Aza-benzothiophenyl compounds and methods of use
AU2007286807B2 (en) 2006-08-21 2013-03-21 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
ATE531720T1 (de) * 2006-08-21 2011-11-15 Genentech Inc Aza-benzofuranylverbindungen und anwendungsverfahren dafür
CN105106199A (zh) 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2008157179A2 (en) 2007-06-12 2008-12-24 Genentech, Inc. N-substituted azaindoles and methods of use
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AR067413A1 (es) 2007-07-05 2009-10-07 Genentech Inc Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
KR101624361B1 (ko) * 2007-07-05 2016-05-25 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
JP5453290B2 (ja) 2007-11-12 2014-03-26 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
US8293763B2 (en) 2007-12-19 2012-10-23 Genentech, Inc. 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
JP5421925B2 (ja) * 2007-12-19 2014-02-19 ジェネンテック， インコーポレイテッド ５−アニリノイミダゾピリジン及び使用の方法
EP2220092B1 (en) * 2007-12-21 2012-06-06 Genentech, Inc. Azaindolizines and methods of use
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
AU2009204025B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
BRPI0910200A2 (pt) * 2008-07-01 2015-09-29 Genentech Inc composto, composição farmacêutica, método de inibir o crescimento de células anormais ou de tratar um distúrbio hiperproliferativo em um mamífero e método de tratar uma doença inflamatória em um mamífero
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
HRP20160044T1 (hr) 2008-08-04 2016-02-26 Merck Patent Gmbh Novi spojevi fenilamino izonikotinamida
CA2742945A1 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011047788A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
CN102574782B (zh) 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 取代的卤代苯氧基苯甲酰胺衍生物
RU2571930C2 (ru) 2010-02-25 2015-12-27 Дана-Фарбер Кэнсер Инститьют, Инк. Мутации braf, обеспечивающие резистентность к ингибиторам braf
US20130059851A1 (en) 2010-03-09 2013-03-07 Dana-Farber Cancer Institute, Inc. Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy
NZ608069A (en) 2010-10-06 2014-06-27 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
CN103282351A (zh) 2010-10-29 2013-09-04 拜耳知识产权有限责任公司 取代的苯氧基吡啶
EP2694072B2 (en) 2011-04-01 2024-08-07 Genentech, Inc. Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
WO2012160130A1 (en) 2011-05-25 2012-11-29 Universite Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CN103204822B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
BR112014029338A2 (pt) 2012-05-31 2017-06-27 Bayer Pharma AG biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc)
NZ706723A (en) 2012-10-12 2018-07-27 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
CA2907704C (en) 2013-03-21 2023-01-10 Giordano Caponigro Combination therapy for reversing b-raf inhibitor resistance comprising a second inhibitor based on genetic alterations
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
US12116348B2 (en) 2017-11-14 2024-10-15 Shenzhen Targetrx, Inc. Substituted benzimidazole compound and composition comprising same
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US6469009B1 (en) * 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
HK1041697A1 (zh) * 1999-01-13 2002-07-19 沃尼尔‧朗伯公司 苯并杂环和它们作为mek抑制剂的用途
JP2002534498A (ja) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤としてのベンゼンスルホンアミド誘導体およびその使用
CA2377092A1 (en) * 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors

Also Published As

Publication number Publication date
CN1652792A (zh) 2005-08-10
RU2004127925A (ru) 2005-05-27
EP1482944A4 (en) 2006-04-19
DOP2003000614A (es) 2009-09-30
EP1482944A2 (en) 2004-12-08
US20060106225A1 (en) 2006-05-18
UA76837C2 (uk) 2006-09-15
PL378635A1 (pl) 2006-05-15
MXPA04008894A (es) 2005-06-20
TW200406203A (en) 2004-05-01
KR20040098013A (ko) 2004-11-18
IL163996A0 (en) 2005-12-18
JP2005526076A (ja) 2005-09-02
CO5611145A2 (es) 2006-02-28
WO2003077855A2 (en) 2003-09-25
WO2003077855A3 (en) 2004-03-04
AU2003220202A1 (en) 2003-09-29
CA2478534A1 (en) 2003-09-25
PA8569201A1 (es) 2004-05-21
RU2300528C2 (ru) 2007-06-10
US20030216460A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
AR038972A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
AR046081A1 (es) Inhibidores heterociclicos de mek y uso de los mismos
AR038971A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
AR051248A1 (es) Derivados de 3-arilamino piridina
DE69515702T2 (de) L-Tertiär-leucin-2-pyridylamid
AR043199A1 (es) Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes
AR044403A1 (es) Derivados de oximas y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR038883A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos
PT83521B (pt) Processo para a preparacao de novos derivados biciclicos naftalenicos e das respectivas composicoes farmaceuticas e cosmeticas
DE69822214D1 (de) ((cyclo)alkyl substituierte)-.gamma.-aminobuttersäure derivate (=gaba analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen
ECSP055636A (es) Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa
CY1108827T1 (el) Μονο-υποκατεστημενα 3-προπυλο γαμμα-αμινοβουτυρικα οξεα
CY1116119T1 (el) Παραγωγα ισοξαζολο-πυριδινης
HRP20020475B1 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
CY1108557T1 (el) Ν-οξειδια ως ανταγωνιστες υποδοχεων νκ1, προφαρμακα παραγωγων της 4-φαινυλο-πυριδινης
KR900017476A (ko) 살진균제, 및 치환된 아미노산 아미드 유도체 및 이의 제조방법
JPS58185553A (ja) α−保護されたオキシイミノ−β−ケト−γ−ハロゲノ酪酸類
Coyne et al. Anticonvulsant semicarbazides
DE602004031338D1 (de) Isochinolin-1,3,4-trion, synthetisches verfahren und dessen verwendung
BRPI0416564A (pt) novas prostamidas para o tratamento de glaucoma e doenças relacionadas
DE68904342D1 (de) Cyclische amide.
CY1108148T1 (el) Αβερμεκτινης- και μονοσακχαριτη αβερμεκτινης παραγωγα υποκατεστημενα στην 4''- ή 4'- θεση που εχουν ζιζανιοκτονες ιδιοτητες
ATE548042T1 (de) Prostansäurederivate zur senkung des augeninnendrucks
BRPI0417844A (pt) derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina
ATE86612T1 (de) Hetera-aliphatische carboxamide.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal